My-Lien Nguyen1, Ana Mohammad-Zadeh2, Greg Krempl3,4, Mohammad Razaq4,5, Lindsey Collins6, Talal Zahoor6, Daniel Zhao4,7, Christina Henson1,4. 1. Department of Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. 2. College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. 3. Department of Otorhinolaryngology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. 4. Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. 5. Department of Internal Medicine, Hematology/Oncology Section, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. 6. Department of Dermatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. 7. Department of Biostatistics and Epidemiology, Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Abstract
BACKGROUND: Merkel cell carcinoma (MCC) is a rare, highly aggressive malignancy which lacks high-level evidence-based treatment guidelines. METHODS: To determine outcomes of MCC patients and assess the role of radiation in treatment, we performed a retrospective chart review of patients treated for MCC between 2006 and 2016 at a single high-volume academic medical center. The primary outcome was overall survival (OS) for the entire population and for those populations receiving specific therapies. RESULTS: Forty-two patients were evaluable. OS for all patients was not reached since most remain alive at time of analysis. OS for the American Joint Committee on Cancer (AJCC) stage I was not reached. OS for stages II, III, and IV was 37.3 months (6.8, -), 49.5 months (14.2, 49.5), and 14.5 months (10.8, -), respectively. OS could not be reached in the high radiotherapy (RT) dose group (biologically equivalent dose [BED] ≥ 60) and was 49.5 months (10.8, -) in the low-dose group (BED < 60). For surgical margin status, OS was 14.9158 months (6.8008, -) for positive margins and 37.3 months (10.8, -) for negative margins. CONCLUSIONS: No conclusive findings for OS were identified; however, trends for improved OS were associated with lower AJCC staging, negative surgical margins, and high RT doses.
BACKGROUND: Merkel cell carcinoma (MCC) is a rare, highly aggressive malignancy which lacks high-level evidence-based treatment guidelines. METHODS: To determine outcomes of MCC patients and assess the role of radiation in treatment, we performed a retrospective chart review of patients treated for MCC between 2006 and 2016 at a single high-volume academic medical center. The primary outcome was overall survival (OS) for the entire population and for those populations receiving specific therapies. RESULTS: Forty-two patients were evaluable. OS for all patients was not reached since most remain alive at time of analysis. OS for the American Joint Committee on Cancer (AJCC) stage I was not reached. OS for stages II, III, and IV was 37.3 months (6.8, -), 49.5 months (14.2, 49.5), and 14.5 months (10.8, -), respectively. OS could not be reached in the high radiotherapy (RT) dose group (biologically equivalent dose [BED] ≥ 60) and was 49.5 months (10.8, -) in the low-dose group (BED < 60). For surgical margin status, OS was 14.9158 months (6.8008, -) for positive margins and 37.3 months (10.8, -) for negative margins. CONCLUSIONS: No conclusive findings for OS were identified; however, trends for improved OS were associated with lower AJCC staging, negative surgical margins, and high RT doses.
Authors: Howard L Kaufman; Jeffery Russell; Omid Hamid; Shailender Bhatia; Patrick Terheyden; Sandra P D'Angelo; Kent C Shih; Céleste Lebbé; Gerald P Linette; Michele Milella; Isaac Brownell; Karl D Lewis; Jochen H Lorch; Kevin Chin; Lisa Mahnke; Anja von Heydebreck; Jean-Marie Cuillerot; Paul Nghiem Journal: Lancet Oncol Date: 2016-09-01 Impact factor: 41.316
Authors: Michelle M Chen; Sanziana A Roman; Julie A Sosa; Benjamin L Judson Journal: JAMA Otolaryngol Head Neck Surg Date: 2015-02 Impact factor: 6.223
Authors: Tobin Strom; Michael Carr; Jonathan S Zager; Arash Naghavi; Franz O Smith; C Wayne Cruse; Jane L Messina; Jeffery Russell; Nikhil G Rao; William Fulp; Sungjune Kim; Javier F Torres-Roca; Tapan A Padhya; Vernon K Sondak; Andy M Trotti; Louis B Harrison; Jimmy J Caudell Journal: Ann Surg Oncol Date: 2016-06-01 Impact factor: 5.344
Authors: Kelly G Paulson; Song Youn Park; Natalie A Vandeven; Kristina Lachance; Hannah Thomas; Aude G Chapuis; Kelly L Harms; John A Thompson; Shailender Bhatia; Andreas Stang; Paul Nghiem Journal: J Am Acad Dermatol Date: 2017-11-02 Impact factor: 11.527
Authors: Kelly L Harms; Mark A Healy; Paul Nghiem; Arthur J Sober; Timothy M Johnson; Christopher K Bichakjian; Sandra L Wong Journal: Ann Surg Oncol Date: 2016-05-19 Impact factor: 5.344